drugset / Trial / NCT00239577

A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults

NCT00239577 ↗

Phase 2 Completed 86 enrolled GlaxoSmithKline
RandomizedParallel-groupPrevention

Summary

This descriptive study will evaluate the safety and immunogenicity of 5 different formulations of the WRAIR dengue vaccine compared to a placebo.

Timeline

Start
2006-04-05
Primary completion
2007-06-19
Completion
2007-06-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Live attenuated tetravalent dengue vaccine Vaccine — Subcutaneous

Indications